Challenges in the Federal Regulation of Pain Management Technologies
- 1 January 2003
- journal article
- review article
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 31 (1), 55-74
- https://doi.org/10.1111/j.1748-720x.2003.tb00059.x
Abstract
Those who write about pain management have focused almost entirely on delivery issues, paying essentially no attention to the federal regulatory challenges that affect the development of pain relief technologies — namely, pharmaceuticals and medical devices indicated for analgesic uses. The academic literature is strangely devoid of any sophisticated discussion of the difficulties that attend, first, the product approval decisions of the Food and Drug Administration (FDA) and, second, the scheduling decisions made by the Drug Enforcement Administration (DEA). If a “bottleneck” develops upstream, it could have serious repercussions downstream — without pain relief technologies, the issues of access that have preoccupied previous commentators would have little practical consequence.The modern pharmaceutical industry traces its origins back more than a century, around the time that the German company Bayer first synthesized aspirin (acetylsalicylic acid) and began marketing it as an analgesic.Keywords
This publication has 63 references indexed in Scilit:
- Physician-Assisted Suicide in Oregon — An Uncertain FutureNew England Journal of Medicine, 2002
- Controlled Substances and Pain Management: Changes in Knowledge and Attitudes of State Medical RegulatorsJournal of Pain and Symptom Management, 2001
- The Architecture of Government Regulation of Medical ProductsVirginia Law Review, 1996
- Opioid AnalgesicsDrugs, 1996
- The Mechanisms of Action of NSAIDs in AnalgesiaDrugs, 1996
- The pharmacogenetics of codeine hypoalgesiaPharmacogenetics, 1995
- Federal Regulation of Clinical Practice in Narcotic Addiction Treatment: Purpose, Status, and AlternativesPublished by Cambridge University Press (CUP) ,1994
- The Treatment of Anxiety: Realistic Expectations and Risks Posed by Controlled SubstancesJournal of Law, Medicine & Ethics, 1994
- Nationalism Chinese StyleThe Antioch Review, 1988
- Improving Drug-Therapy Decisions through Educational OutreachNew England Journal of Medicine, 1983